Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Ikeguchi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Alexandra Ikeguchi is an oncologist in Houston, TX and is affiliated with UT MD Anderson Cancer Center. She received her medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 25 years. She specializes in melanoma and is experienced in squamous cell carcinoma, melanoma, mucosal melanoma, merkel cell carcinoma, and uveal neoplasms. She has 8 publications and over 50 citings.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1995 - 1998- New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1992 - 1995
Columbia University Vagelos College of Physicians and SurgeonsClass of 1992
Certifications & Licensure
FL State Medical License 2023 - Present
AZ State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
TX State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2024 - 2025
GA State Medical License 2023 - 2025
American Board of Internal Medicine Hematology- Join now to see all
Clinical Trials
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
- Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients Start of enrollment: 2012 Dec 01
- Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 12
- Join now to see all
Publications & Presentations
PubMed
- Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific.Joseph J Sacco, Peter Kirk, Emma Leach, Alexander N Shoushtari, Richard D Carvajal
Cell Reports. Medicine. 2025-04-15 - 1 citationsThe Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.Caroline E Dravillas, Samuel S Coleman 4th, Rebecca Hoyd, Griffin Caryotakis, Louis Denko
Cancer Research Communications. 2024-08-01 - Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors.Xuefeng Wang, Tingyi Li, Islam Eljilany, Vineeth Sukrithan, Aakrosh Ratan
Medrxiv. 2024-07-21
Press Mentions
ECOG-ACRIN Cancer Research Group Melanoma Research Team Led by Michael Atkins, MD, Receives the 2023 Paper of the Year Distinction from the Journal of Clinical OncologyJanuary 19th, 2024
Grant Support
- Immunotherapy of Uveal Melanoma using PRAME Vaccine in Combination with Adoptive T Cell TherapyUNIVERSITY OF TX MD ANDERSON CAN CTR2022–2028
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
